|
Sep 26
|
Biotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More
|
|
Sep 20
|
VNDA Stock Down as FDA Rejects NDA for Tradipitant in Gastroparesis
|
|
Sep 20
|
Novo sinks on obesity drug results; Sanofi reveals anticipated MS data
|
|
Sep 20
|
FDA declines approval of Vanda’s gastroparesis treatment
|
|
Sep 19
|
Why Vanda Pharmaceuticals Stock Sank by Nearly 6% Today
|
|
Sep 19
|
FDA Declines to Approve Vanda's Marketing Application for Tradipitant in Gastroparesis
|
|
Aug 29
|
Vanda Pharmaceuticals Announces Participation in the Wells Fargo 2024 Healthcare Conference
|
|
Jul 26
|
Vanda Pharmaceuticals to Announce Second Quarter 2024 Financial Results on July 31, 2024
|
|
May 29
|
Vanda Pharmaceuticals Announces Presentations at SLEEP 2024
|
|
May 24
|
Vanda Pharmaceuticals Board of Directors Determines that Revised Unsolicited Takeover Proposal is Not in the Best Interests of the Company and its Shareholders
|
|
May 15
|
Vanda Pharmaceuticals Reports Positive Results from a Second Phase III Study of Tradipitant in Motion Sickness
|
|
May 10
|
Vanda Pharmaceuticals Reports Mixed Q1 2024 Results, Misses Revenue Estimates
|
|
May 9
|
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q1 2024 Earnings Call Transcript
|
|
May 9
|
Q1 2024 Vanda Pharmaceuticals Inc Earnings Call
|
|
May 9
|
Vanda Pharmaceuticals Inc (VNDA) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...
|
|
May 8
|
Vanda Pharmaceuticals Reports First Quarter 2024 Financial Results
|
|
May 7
|
Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak
|
|
May 7
|
UPDATE 3-Future Pak sweetens take-private offer for Vanda Pharmaceuticals
|
|
Apr 30
|
Vanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024
|
|
Apr 25
|
UPDATE 1-Shareholder Capital asks Vanda Pharma's board to reconsider Future Pak's offer
|